Eli Lilly to Appeal UK Rejection of Alzheimer's Drug Kisunla Impacting Thousands of Patients

Eli Lilly, a U.S.-based pharmaceutical company, has announced plans to appeal the UK health agency's decision to reject reimbursement for its Alzheimer's drug Kisunla, effectively blocking access for patients under the state-run National Health Service (NHS).

The National Institute for Health and Care Excellence (NICE) deemed Kisunla too expensive for widespread use, despite its approval in the UK last year for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease. Lilly argues that NICE’s recommendation is unreasonable, citing clinical evidence provided by the company, medical experts, and patient advocacy groups.

This ruling marks the second major regulatory setback for Kisunla, following the European Medicines Agency's rejection in March, which concluded that the drug's ability to slow cognitive decline was not significant enough compared to the risk of brain swelling in patients.

Kisunla, along with its rival drug Leqembi (developed by Eisai and Biogen), is designed to target amyloid beta, a protein associated with Alzheimer's disease. However, the adoption of these drugs has been slow globally due to the need for frequent diagnostic tests and brain scans to monitor side effects.

Eli Lilly’s appeal reflects its commitment to making Kisunla accessible, as Alzheimer's disease continues to devastate millions of lives worldwide. The drug is seen as a crucial step forward in combating the disease, despite challenges in regulatory approval and affordability.